With evidence that high expression of the adhesion protein JAM-A marks aggressive disease in patients with invasive breast ductal carcinoma [8,9,10,11,12], this study set out to determine if JAM-A expression was also elevated at the earlier phase of DCIS. This evidence concerns the gene F11R and ductal breast carcinoma in situ.